Tirelizumab in Combination With Carboplatin and Albumin-binding Paclitaxel for Neoadjuvant Therapy in HNSCC

NCT05941338 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma
Oral Cancer

Interventions

DRUG: Tirelizumab ,+Carboplatin+albumin-bound paclitaxel

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University